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The prevention ofmalaria infections is one ofthe most important functions that anyclinician
can perform for those traveling to tropical geographic regions where malaria risks are present.
The prophylaxis question has become complicated by continued emergence of chloroquine-
resistant strains of Plasmodium falciparum, the recent appearance of Plasmodium vivax resis-
tance, and the availability of a wide choice ofantimalarial pharmaceuticals. Chemoprophylaxis
may produce different toxicities among various patient populations. With increasing numbers
of women who travel during their professional lives, there are potential implications for using
chemoprophylaxis during pregnancy. Children are unable to tolerate certain antimalarials
because of toxicities unique for them. In some instances, the safest and most palatable
formulations for children are not even available in the United States and must be purchased in
Canada or elsewhere. Reliance upon chemoprophylaxis alone has proven to be increasingly
futile. With the introduction of new repellent formulations and nontoxic insecticides for use on
clothing or bed netting, there are non-pharmacologic adjunctive measures which can now be
considered first-line for the prevention ofmalaria infections.
The prevention of malaria infections caused by one of the four known species of
human plasmodia is based upon an understanding ofthe natural history of infection
in both the mosquitovector and the human host. Malaria is transmitted to humansby
the bite of an infected female anopheline mosquito, which utilizes a blood meal in
the development of its eggs. Infective sporozoites, which the mosquito introduces
into the host during biting, circulate in the peripheral blood for a period of only
minutes before infecting the human liver. No clinical disease is evident at this stage
of infection. Once merozoites have developed and are released from the liver into
the circulation, they infect erythrocytes. The development of the asexual malaria
parasites within erythrocytes ultimately leads to the destruction of infected erythro-
cytes and the release of additional infective merozoites. Some erythrocytic forms of
the malaria parasite are destined to become sexual forms, either microgametocytes
or macrogametocytes. They will continue the malaria cycle if they infect feeding
mosquitoes in which sexual reproduction can continue, ultimately leading to the
production ofadditional sporozoites to cause future human infections.
ADJUNCTIVE MEASURES FOR THE PREVENTION OF MALARIA:
ALTERNATIVES TO CHEMOPROPHYLAXIS
During the past 50 years, since the discovery of chloroquine, if a physician were
preparing travelers entering malarious areas, considerable emphasis would have
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been placed on the prevention of clinical disease, as opposed to the prevention of
human infection. The latter can only be accomplished by controlling mosquito
populations and their contact with humans. Chemoprophylaxis, as currently advo-
cated, does not affect sporozoites and does not prevent malaria infections; it does
stop the replication of malarial parasites in liver or erythrocytes [1]. Prophylactic
agents,which primarily affect the erythrocytic stages and prevent clinical disease, are
called suppressive. Those which affect liver forms and prevent release into the
circulation are known as causal prophylactics.
There were many social and economic factors contributing to such a pharmaceuti-
cal approach, including the cost ofspraying programs and the environmental toxicity
associated with the use of insecticides. In addition, by the 1940s, U.S. research on
antimalarial drugs was intensified due to the ongoing war with Japan in the Pacific.
One derivative of the 4-aminoquinolones, SN 7618, was found to be both safe and
extremely active against all species of human malaria [2]. This agent became known
to a generation ofphysicians as chloroquine, and it had avery long period ofclinical
usefulness. To some extent, it still is very useful.
By the early 1960s, chloroquine use was becoming quite extensive, and the
International Cooperation Administration was purchasing nearly 200,000 pounds of
powdered chloroquine for a single medicated salt program to prevent malaria in
Brazil. Over 88,000,000 tablets of chloroquine diphosphate were purchased for
therapy in Brazil during one year alone [2]. With such intensive and widespread use
ofchloroquine, it was not surprising that chloroquine resistance emerged during the
followingdecades, although the mechanismofresistance and its emergence were not
really understood. This pattern of initial enthusiasm for antimalarial agents, fol-
lowed by their extensive use, and the gradual loss ofprophylactic efficacy due to the
emergence ofdrug-resistant malaria strains has been repeated with other antimalar-
ial agents. The problem continues to spread worldwide; therefore, we begin our
discussion of malaria prophylaxis with a consideration of barrier methods for the
prevention of contact between mosquito vectors and humans. The clear aim is
effectively to prevent human malaria infections, not only disease, thereby reducing
the need to rely only upon chemoprophylaxis.
Mosquitoes which transmit malaria often bite at dusk. It is best to wear long-
sleeved shirts and long pants when outdoors at such times in order to prevent
mosquito bites. There are several agents which are considered fairly useful topical
insect repellents [3]. Out of this array of compounds, one of the most effective and
readily available agents is N, N-diethyl-m-toluamide, or DEET. There are many
commercial formulations, some ofwhich contain nearly 100 percent DEET [3], but
there is a price to be paid if they are misused. Focal allergic reactions, blisters,
ulcerations, and skin necrosis have been reported. About 10 to 15 percent of a dose
applied to the skin is absorbed and excreted in the urine. Toxic encephalopathy
occurred in children who were sprayed repeatedly with 10-15 percent DEET
preparations over periods from days to months, and one eight-year-old child has
experienced seizures while using 100 percent DEET [4]. This repellent is quite
useful, however, and it is now available as a one-ounce cream in a micronized
encapsulated form and 35 percent concentration, which apparently provides protec-
tion for up to 12 hours following application (Ultrathon, Sports Products, 3M, St.
Paul, MN). In this physical form, evaporation is diminished. Since less frequent
applications are effective, the possibility of toxic reactions is likely to be diminished.
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DEET can also be applied to clothing rather than to skin and offers protection
without intense skin exposure; however, there are better alternatives for treating
both clothing and bed netting.
Permethrin is a nontoxic, odorless pesticide, which is somewhat resistant to light,
heat, and water immersion [4]. It is available as a spray or solution (Travel Medicine
Inc, Northampton, MA; telephone: 800-872-8633) and can be used to impregnate
bed nets or clothing. It apparently binds tightly to fabrics and lasts through several
washings. Clinical trials in tropical areas of east Africa have shown permethrin-
impregnated bed nets and curtains to be quite effective in village-wide malaria
prevention programs [5]. Mosquito nets are available in several lightweight models
with convenient carrying cases, in either free-standing or hanging models for one or
two beds. The netting fabric should also be treated with about two ounces of
permethrin. To reiterate, permethrin is an insecticide and not simply a mosquito
repellent, thus offering considerable additional protection when used in conjunction
with bed nets and topical repellents such as DEET.
Pyrethrum is a nontoxic natural derivative of the chrysanthemum flower. As an
alternative to DEET, pyrethrum-containing sprays and mosquito coils can be used
for children's sleeping quarters in order to diminish mosquito exposure at night.
Each of these preventive measures should be carefully considered and incorporated
into any plan for the prevention ofmalaria before attempting to utilize pharmaceuti-
cal agents to which Plasmodium species are becoming increasingly resistant [6].
PHARMACEUTICAL AGENTS FOR PREVENTION OF MALARIA
Chloroquine Salts andAmodiaquine
For chemoprophylaxis against P. vivax, P. ovale, P. malariae, and chloroquine-
sensitive strains of P. falciparum, chloroquine phosphate is still a safe and useful
suppressive drug. Because of its bitter taste, it is often prescribed as an enteric-
coated tablet (Aralen®, Winthrop), containing 300 mg ofchloroquine base as 500 mg
of the salt. Prophylaxis is usually initiated one week before reaching a malarious
region. It is continued for four weeks after leaving the malarious area. The 50
percent effective dose (IC50) for chloroquine is analogous to the minimum inhibitory
concentration used to describe the activity of antibacterial agents. Chloroquine's
IC50s are in the range of 2 to 32 nM for chloroquine-susceptible strains of P.
falciparum [7]. Chloroquine reaches serum levels of about 50 to 100 nM, with a
half-life of about 6-13 days; hence it is quite acceptable as a weekly prophylactic
agent. Adverse chloroquine effects are not usually a serious problem but do include
pruritus, headache, gastrointestinal symptoms, and fatigue. Because ofchloroquine's
affinity for melanin in tissues, the possibility of retinopathy is often a point of
concern. Retinopathy is not associated with routine short-term chloroquine prophy-
laxis given on a weekly basis, resulting in total doses offar less than 100 grams. It is
thought that chloroquine may exacerbate psoriasis, but there are little data indicat-
ing that this reaction is a significant problem. Since patientswho are HIV-infected do
have a higher incidence and severity of psoriasis, this result could be a potential
problem towatch forwhenusingchloroquine in thispatient population. Chloroquine
is known to interfere with the antibody responses to human diploid cell rabies
vaccine, but it does not appear to interfere with the response to yellow fever vaccine
[8]. Chloroquine is safe for malaria prophylaxis during pregnancy, but the spread of
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chloroquine-resistant P. falciparum (CRPF), and the recent appearance of chloro-
quine-resistant P. vivax in Iryan Jaya (Indonesian New Guinea) will surely diminish
its reliability [9]. This development is unfortunate, given the lack of a suitable
alternative agent for use during pregnancy in chloroquine-resistant malaria regions.
Although amodiaquine has greater activity than chloroquine against some strains of
P. falciparum with low-level chloroquine resistance, it is no longer recommended as
an alternative agent to chloroquine because of reported cases of hepatitis and
agranulocytosis [6].
Mefloquine
The antimalarial agent which has largely replaced chloroquine as a suppressive
agent in areas where chloroquine resistance has been problematic is the quinoline
methanol, mefloquine (Lariam®), which is somewhat similar in structure to quini-
dine and quinine. Mefloquine has a half-life ofabout 17 to 22 days, an advantage for
purposes ofchemoprophylaxis. This period is even longerthan chloroquine's, but not
long enough for it to be used on an every-other-week basis. When alternate-week
prophylaxis was attempted in Peace Corps volunteers working in west Africa,
prophylaxis failures occurred during the second week [10]. The currently accepted
prophylactic regimen is 250 mg weekly for adults, beginning one week before and
continuing until four weeks after leaving a malarious region. Adverse effects are
dose-related and are largely associated with gastrointestinal disturbances and dizzi-
ness. These effects appear to be pronounced in children. Splitting the weekly dose
into two doses may help to diminish the gastrointestinal effects for both adults and
children. Fears regarding possible neuropsychiatric disturbances in patients taking
this agent for prophylaxis have not materialized. Mefloquine should not be given to
patients who are receiving beta blockers or calcium channel antagonists because
mefloquine has been associated occasionallywithboth sinusbradycardia and prolon-
gation ofthe Q-T interval. The drug had appeared safe for use duringpregnancy, but
it is not approved for such purpose. At present, mefloquine is actuallyplaced in FDA
Pregnancy Category C, on the basis of embryotoxic and teratogenic effects. Use
during pregnancy hasbeen associatedwith reduced fetal growth and cleftpalate [11].
Women with childbearing potential should be advised to use contraception both
while takingmefloquine prophylaxis and for two months after their last doses.
Sulfadoxine/Pyrtimethamine
In areas where CRPF is endemic, Fansidar® (500 mg sulfadoxine and 25 mg of
pyrimethamine) had been used forpresumptive treatment ofa febrile illness thought
to represent malaria. The combination had also been used as part of a weekly
regimen ofprophylaxis duringprolonged exposure to CRPF. Resistance appeared in
east Africa and rural Thailand, but one factor limiting its use was the appearance of
severe adverse cutaneous reactions, including toxic epidermal necrolysis, erythema
multiforme, and Stevens-Johnson syndrome, from which several deaths resulted [6].
Patients should be instructed to stop this medication and seek medical attention if
they experience a cutaneous reactionwhile taking it. The need formedical attention
is also based upon the assumption that another agent will be substituted for
prophylaxis if the reaction is found to be potentially serious. Sulfadoxine competes
with bilirubin and can exacerbate neonatal jaundice. Pyrimethamine has not been
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shown to be a human teratogen, but it is teratogenic in animals. We would still not
recommend the use ofthis combination during the third trimester ofpregnancy.
Doxycycline
In areas such as Thailand, where there is now considerable resistance to many
antimalarials, including mefloquine, the tetracyclines have gained an important role
in malaria prophylaxis. Recall that tetracyclines, proguanil, and pyrimethamine are
examples of causal prophylactic drugs, which have activity against the exoerythro-
cytic hepatic forms [6], in addition to suppressing symptoms via their action on
erythrocytic asexual forms ofthe parasite. Doxycycline (100 mg/day) can be used in
geographic areas where there is CRPF risk, or for patients who are allergic to sulfa
drugs. The problems of both Fansidar® resistance and emerging mefloquine resis-
tance, particularly in Thailand, can be approached by using daily doxycycline
prophylaxis, while in such a region and for four additional weeks after leaving.
Adverse effects include photosensitivity reactions. These canbeprevented byusing a
broad-spectrum sunscreen (e.g., Photoplex®) to block those ultraviolet light wave-
lengths (UVA) responsible for photosensitivity reactions. Women should carry an
antifungal preparation for the treatment of possible candida vaginitis secondary to
tetracycline use. Tetracyclines are not to be used in children less than eightyears old
since they inhibit bone growth and may cause discoloration and dysplasia of teeth.
Tetracyclines are also contraindicated during pregnancy because their effects on the
fetus are similar to their effects in young children.
Proguanil (Chloroguanide)
Proguanil (Paludrineg) is a biguanide agent which, like pyrimethamine, is a
dihydrofolate reductase inhibitor. Most experience with the agent was with doses of
100 mg/day, and the recommended daily dose is 200 mg/day. Although proguanil is
effective in some geographic areas, it is not very useful in others, such as Papua New
Guinea or Thailand [6]. Proguanil is continued for four weeks after leaving a
malarious region, and it appears to be safe during pregnancy, although not much
information is available for the dose of200 mg/day. Proguanil is not available in the
United States and must be purchased in Canada or elsewhere.
TERMINAL PROPHYLAXIS WITH PRIMAQUINE
Both P. vivax and P. ovale produce latent infections in the human liver. If not
eradicated, these latent forms or hypnozoites may cause relapsing infections months
to years after a traveler leaves a malarious region. To prevent such relapses from
occurring, the physician administers the 8-aminoquinolone, primaquine, 15 mg base
orally for 14 days following the final fourweeks ofchloroquine prophylaxis. Patients
with the severe forms ofglucose-6-phosphate dehydrogenase (G6PD) deficiency can
develop hemolysis while taking primaquine, and patients with the severe Mediterra-
nean form of the deficiency should not be given this agent. If malaria relapses do
occur in such patients, they can be treated with chloroquine. Occasionally, prima-
quine use may be associated with some nausea, vomiting, or headache. For women
who are pregnant, chloroquine should be used each week, when exposure toP. vivax
or P. ovale occurs; it can be continued throughout pregnancy and primaquine use
delayed until after delivery. Neither terminal prophylaxis nor so-called radical cure
with primaquine are indicated during pregnancy. The effects of this agent on the
333FRANK J. BIA
fetus are not known, and there is the theoretical possibility that a G6PD-deficient
fetus could experience an episode of hemolysis in utero because the drug may be
passed transplacentally.
We reported a failure of primaquine to prevent a relapse of P. ovale in a Yale
physician who acquired a mixed malaria infection while traveling in Kenya [12]. It is
not known whether the standard 15 mg (base) dosage regimen of 14 days was too
little for a 100 kg (220-pound) man, or whether P. ovale is relatively more resistant
than P. vivax to this agent. For this patient, a 30 mg dose regimen seems to have
ended hisproblem withrelapses; however, we recently had a similar experience with
an average-sized student who returned from Borneo in August of 1991. After
receiving appropriate mefloquine prophylaxis, she required treatment for what
appeared to be vivax malaria seven weeks aftercompleting her course ofmefloquine
prophylaxis. Because ofmanufacturing problems associated with the unavailability
of primaquine in 1991, she had not received any primaquine nor any information
regarding its use. It was then administered in early November, in a dose of 15 mg
base per day for two weeks, only to have her present with a relapse during her
Christmas holidays while visiting family in Virginia. Like our physician-patient, she
also required a course of 30 mg per day in an attempt to prevent further relapses.
Thisdevelopment isnot an unusual occurrence(13], andprimaquine will probablybe
replaced by a more efficacious agent in the near future.
PROPHYLAXIS AND COMPLIANCE IN CHILDREN
Motherswho arebreastfeeding andtakingany antimalarial agents should be made
aware that insufficient drug is transferred to the infant in breast milk for it to serve as
an effective prophylactic agent in a child. Infants require their own regimen of
antimalarial prophylaxis. Toprevent malaria in children, the use of barrier methods
should be emphasized, avoiding exclusive reliance upon chemoprophylaxis, since
there are always issues ofcompliance and efficacywhen using pharmaceutical agents
in children. To increase compliance with the use of chloroquine, parents should
purchasechloroquine suspension (Nivaquine) overseas, since it is not available in the
United States. If the parent is unable to obtain it, Plaquenil® (hydroxychloroquine)
can be purchased in the United States. When pulverized and mixed with food, it is
less bitter and is more tolerated. Regimens for prophylaxis based upon use of
chloroquine are still useful in Haiti, Central America, and the Middle East. Resis-
tance ofP. vivax tochloroquine isemerging in IryanJaya [9] and may be problematic
forother malaria areas in the future. Mefloquine is a useful agent in children who are
more than 15 kg (33 pounds) in weight. If smaller, they may not tolerate the drug
because of nausea, vomiting, or dizziness. There are no available data on meflo-
quine's safety for children under this size which would allow its use. Because
resistance tomefloquine hasalreadyemerged inThailand, it is no longer relied upon
in that area. Adultsmay use adailyregimen ofdoxycycline, which is contraindicated
in children under the age of eight. It has been suggested that the combination of
proguanil and sulfisoxazole (sulfafurazole) could provide greater than 95 percent
protectionagainstfalciparum malaria in such areas, with 100 percent efficacy against
vivax malaria [14]. Afterleavinggeographic regions where vivax malaria occurs, both
children and adults should be given terminal prophylaxis with primaquine after
appropriate screening for any of the severe forms of G6PD deficiency. Keep all
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antimalarials,particularly chloroquine, stored in childproofcontainers, as overdosage
can easily result in a fatality.
Pregnant women are at greater risk of causing fetal growth retardation or fetal
loss, if clinical malaria occurs during pregnancy. As a general rule, travel to areas
where chlorquine-resistant malaria is endemic should be avoided by pregnant
women [15]; there are too few pharmacological options to offer them. The best
alternatives to chloroquine are physical methods for the prevention of mosquito
contact, including long-sleeved clothing treated with permethrin-containing insecti-
cides and the repellent, DEET. Primaquine should not be used during pregnancy for
terminal prophylaxis, but chloroquine can be continued during pregnancy until
delivery, after which primaquine may be administered. Alternatives to chloroquine
during pregnancy include proguanil, which is not effective in some areas of west
Africa, Thailand, and Papua, New Guinea. Fansidar® can be carried for presumptive
treatment offebrile episodes potentially due to falciparum malaria. The risks appear
to be minimal in relation to the risks associated with the occurrence of falciparum
malaria during pregnancy. The reader is referred to a complete discussion of such
issues during pregnancy and a review of toxicities associated with antimalarial
medications during pregnancy [15].
Malaria prophylaxis has come full circle. With an imperfect understandingofboth
the transmission and pathogenesis of malaria infections in the past, it was still
possible to reduce malaria transmission by draining swamps and removing breeding
sites for anopheline mosquitoes. The advent of chemoprophylaxis with the agents
described above has not solved the problem, as the emergence of resistance to
antimalarials has shown us. For a listing ofcurrently recommended dosing schedules
for the antimalarials described here, the reader is referred to the most recent issue of
The Medical Letter, which appears every other year in March [17]. This publication
includes the most recent recommendations on the use ofantimalarial agents forboth
adults and children. When advising those who are living, working, or vacationing in
malarious regions, however, physicianswho stafftravelers' clinicswill now emphasize
some ofthe newest developments in the use ofbarrier methods for the prevention of
malaria infections [15,16]. Ultimately, reduction in contact between humans and
infected anopheline mosquitoes will be one key to malaria prevention.
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